Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + abiraterone as neoadjuvant therapy for high-risk localized prostate cancer
ChiCTR2100046198Phase 2Completed
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and abiraterone in prostate cancer (PCa), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Pathological remission rate. Started May 2021; status: completed.
02
Drugs
fluzoparibabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2100046198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046198.